You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明生物續漲近4.5%破頂 君實/微創/四環/聯邦制藥漲4%-5%
阿思達克 08-27 14:04
下月7日正式「染藍」的藥明生物(02269.HK)承昨天回升近6%勢,今天股價進一步突破本月6日所創上市高位193元,最高見200元,現造196.7元,續升4.4%,成交608萬股(已接近昨天全日成交668萬股),涉資11.94億元。

聯邦制藥(03933.HK)昨天收市後公布中績少賺31.5%至2.03億人民幣及營收年增5%,今早低開回落至8.43元獲承接,掉頭高見9.17元,暫受制昨天盤中所創逾兩年高位9.21元,現造9.09元,續升5%。

日前公布中績虧轉賺1.5億人民幣中期共派息3.1分人民幣的四環醫藥(00460.HK)扭兩連吐股價重越10天線(0.92元),最高見0.95元,現造0.94元,回升4.4%。

微創醫療(00853.HK)扭三連跌股價重越10天線(34.9元),最高見35.15元,現造35.1元,回升4.8%。君實生物(01877.HK)也扭三連跌股價重越10天線(49.2元),報49.95元即市高位,回升4%。

昨天中午放榜中績多賺23%及恢復派發中期息兼送紅股的藍籌石藥集團(01093.HK)高見17.28元,暫受制去年11月所創52周高位18元,現造17元,續升2.2%。

相反,早前公布中績少賺近3%的國藥(01099.HK)續跌2.5%報18.8元。神威藥業(02877.HK)、綠葉製藥(02186.HK)及三生製藥(01530.HK)回吐1.8%-2.3%,分別報5.32元/4.86元/9.1元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account